Oncology News

SAN DIEGO — Black women continue to experience disparities in breast cancer diagnosis and treatment, leading to increased mortality.

SAN DIEGO — In this video, Rochelle F. Andreotti, MD, a professor of clinical radiology, radiological sciences and OB/GYN at Vanderbilt University Medical Center, recaps her endowed lecture on adnexal mass evaluation.

SAN DIEGO — Passively self-collected menstrual blood for the detection of HPV showed results that were highly concordant with clinician-collected sampling and had greater acceptance among patients, researchers reported here.

The FDA expanded the approval of fam-trastuzumab deruxtecan to include treatment of patients with HER2-positive metastatic breast cancer who received a prior anti-HER2-based regimen.

The addition of ribociclib to fulvestrant conferred a survival benefit of nearly 16 months as first-line treatment for postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer, topline data showed.

The FDA granted fast track designation to ofranergene obadenovec in combination with paclitaxel for treatment of platinum-resistant ovarian cancer.

CHICAGO — In this video interview with Healio, Stephanie Faubion, MD, MBA, FACP, NCMP, IF, highlights recent research on women’s health, which she discussed during her presentation here.

In this episode, Amy Comander, MD, Beth Frates, MD, and Michelle Tollefson, MD, discuss their journeys in the breast cancer treatment and awareness space and their new personal well-being resource, PAVING the Path to Wellness Workbook.

The FDA granted breakthrough therapy designation to fam-trastuzumab deruxtecan-nxki for treatment of adults with unresectable or metastatic HER2-low breast cancer, according to a press release from the agent’s manufacturer.

Black/African American and Hispanic/Latina women who have low vitamin D concentrations may be more likely to be diagnosed with breast cancer than those with adequate concentrations, according to a study published in Cancer.